Baez M A, Garg D C, Jallad N S, Weidler D J
Br J Clin Pharmacol. 1986;21 Suppl 1(Suppl 1):63S-67S. doi: 10.1111/j.1365-2125.1986.tb02855.x.
The antihypertensive effect of doxazosin 1-16 mg once-daily was compared with that of atenolol 50-100 mg once-daily, and placebo, utilizing a double-blind parallel group (12 patients each) design. Blood pressure (BP) and pulse rate were determined in out-patients who returned for clinic visits every 2 weeks for 14 weeks. During the first 4 weeks, all patients received single-blind placebo therapy. During the subsequent 10 weeks, patients were randomized to placebo, atenolol or doxazosin treatment. After 2 weeks of doxazosin therapy 16 mg daily, there was a significant decrease from baseline (single-blind placebo period) in supine diastolic BP (P less than 0.01) and standing diastolic BP (P less than 0.001). The decreases in supine and standing diastolic BPs in the doxazosin 16 mg daily group were significantly (P less than 0.01) different from the corresponding BPs of the placebo group. At weeks 12 and 14, heart rates in the doxazosin group were not significantly different from baseline or from those in the placebo group. After 4 and 6 weeks of atenolol 100 mg daily, there was a significant decrease from baseline in both supine (P less than 0.001 and P less than 0.05) and standing (P less than 0.05) diastolic BPs and heart rates (P less than 0.05). However, when the atenolol group was compared with the placebo group, a significant decrease occurred only with supine diastolic BP at week 12 (P less than 0.01) and not at week 14; but significant decreases occurred in supine and standing heart rates at weeks 12 and 14 (P less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
将多沙唑嗪1 - 16毫克每日一次的降压效果与阿替洛尔50 - 100毫克每日一次以及安慰剂的降压效果进行比较，采用双盲平行组设计（每组12例患者）。在14周内，每2周复诊一次的门诊患者的血压（BP）和脉搏率得以测定。在最初4周，所有患者接受单盲安慰剂治疗。在随后10周，患者被随机分为接受安慰剂、阿替洛尔或多沙唑嗪治疗。多沙唑嗪每日16毫克治疗2周后，仰卧位舒张压较基线（单盲安慰剂期）显著降低（P<0.01），站立位舒张压显著降低（P<0.001）。多沙唑嗪每日16毫克组仰卧位和站立位舒张压的降低与安慰剂组相应血压值相比有显著差异（P<0.01）。在第12周和第14周，多沙唑嗪组心率与基线或安慰剂组相比无显著差异。阿替洛尔每日100毫克治疗4周和6周后，仰卧位（P<0.001和P<0.05）和站立位（P<0.05）舒张压及心率均较基线显著降低（P<0.05）。然而，当将阿替洛尔组与安慰剂组比较时，仅在第12周仰卧位舒张压有显著降低（P<0.01），第14周无显著降低；但在第12周和第14周仰卧位和站立位心率有显著降低（P<0.05）。（摘要截选至250字）
